-
- Juan A. Barboza
- 1Department of Cancer Genetics, and
-
- Tomoo Iwakuma
- 1Department of Cancer Genetics, and
-
- Tamara Terzian
- 1Department of Cancer Genetics, and
-
- Adel K. El-Naggar
- 2Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
-
- Guillermina Lozano
- 1Department of Cancer Genetics, and
書誌事項
- 公開日
- 2008-06-01
- DOI
-
- 10.1158/1541-7786.mcr-07-2079
- 公開者
- American Association for Cancer Research (AACR)
この論文をさがす
説明
<jats:title>Abstract</jats:title> <jats:p>Mutational inactivation of p53 is a hallmark of most human tumors. Loss of p53 function also occurs by overexpression of negative regulators such as MDM2 and MDM4. Deletion of Mdm2 or Mdm4 in mice results in p53-dependent embryo lethality due to constitutive p53 activity. However, Mdm2−/− and Mdm4−/− embryos display divergent phenotypes, suggesting that Mdm2 and Mdm4 exert distinct control over p53. To explore the interaction between Mdm2 and Mdm4 in p53 regulation, we first generated mice and cells that are triple null for p53, Mdm2, and Mdm4. These mice had identical survival curves and tumor spectrum as p53−/− mice, substantiating the principal role of Mdm2 and Mdm4 as negative p53 regulators. We next generated mouse embryo fibroblasts null for p53 with deletions of Mdm2, Mdm4, or both; introduced a retrovirus expressing a temperature-sensitive p53 mutant, p53A135V; and examined p53 stability and activity. In this system, p53 activated distinct target genes, leading to apoptosis in cells lacking Mdm2 and a cell cycle arrest in cells lacking Mdm4. Cells lacking both Mdm2 and Mdm4 had a stable p53 that initiated apoptosis similar to Mdm2-null cells. Additionally, stabilization of p53 in cells lacking Mdm4 with the Mdm2 antagonist nutlin-3 was sufficient to induce a cell death response. These data further differentiate the roles of Mdm2 and Mdm4 in the regulation of p53 activities. (Mol Cancer Res 2008;6(6):947–54)</jats:p>
収録刊行物
-
- Molecular Cancer Research
-
Molecular Cancer Research 6 (6), 947-954, 2008-06-01
American Association for Cancer Research (AACR)
